PL204215B1 - Pochodne fenylosulfonyloetylopiperydyny, środek leczniczy, sposób wytwarzania pochodnych fenylosulfonyloetylopiperydyny i ich zastosowanie - Google Patents

Pochodne fenylosulfonyloetylopiperydyny, środek leczniczy, sposób wytwarzania pochodnych fenylosulfonyloetylopiperydyny i ich zastosowanie

Info

Publication number
PL204215B1
PL204215B1 PL361387A PL36138701A PL204215B1 PL 204215 B1 PL204215 B1 PL 204215B1 PL 361387 A PL361387 A PL 361387A PL 36138701 A PL36138701 A PL 36138701A PL 204215 B1 PL204215 B1 PL 204215B1
Authority
PL
Poland
Prior art keywords
compound
hydroxypiperidin
ethanesulfonyl
benzyl
formula
Prior art date
Application number
PL361387A
Other languages
English (en)
Polish (pl)
Other versions
PL361387A1 (en
Inventor
Alexander Alanine
Bernd Buettelmann
Holger Fischer
Neidhart Marie-Paule Heitz
Joerg Huwyler
Georg Jaeschke
Emmanuel Pinard
Rene Wyler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL361387A1 publication Critical patent/PL361387A1/xx
Publication of PL204215B1 publication Critical patent/PL204215B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL361387A 2000-08-21 2001-08-20 Pochodne fenylosulfonyloetylopiperydyny, środek leczniczy, sposób wytwarzania pochodnych fenylosulfonyloetylopiperydyny i ich zastosowanie PL204215B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00117918 2000-08-21
PCT/EP2001/009561 WO2002016321A1 (en) 2000-08-21 2001-08-20 Prodrugs to nmda receptor ligands

Publications (2)

Publication Number Publication Date
PL361387A1 PL361387A1 (en) 2004-10-04
PL204215B1 true PL204215B1 (pl) 2009-12-31

Family

ID=8169594

Family Applications (1)

Application Number Title Priority Date Filing Date
PL361387A PL204215B1 (pl) 2000-08-21 2001-08-20 Pochodne fenylosulfonyloetylopiperydyny, środek leczniczy, sposób wytwarzania pochodnych fenylosulfonyloetylopiperydyny i ich zastosowanie

Country Status (35)

Country Link
US (1) US6407235B1 (enExample)
EP (1) EP1313703B1 (enExample)
JP (1) JP4162991B2 (enExample)
KR (1) KR100589991B1 (enExample)
CN (1) CN1227230C (enExample)
AR (1) AR030373A1 (enExample)
AT (1) ATE386022T1 (enExample)
AU (2) AU2001285894B2 (enExample)
BR (1) BR0113348A (enExample)
CA (1) CA2419279C (enExample)
CY (1) CY1107937T1 (enExample)
CZ (1) CZ303319B6 (enExample)
DE (1) DE60132782T2 (enExample)
DK (1) DK1313703T3 (enExample)
EC (1) ECSP034489A (enExample)
EG (1) EG24293A (enExample)
ES (1) ES2299508T3 (enExample)
HR (1) HRP20030125B1 (enExample)
HU (1) HU229802B1 (enExample)
IL (1) IL154254A0 (enExample)
JO (1) JO2289B1 (enExample)
MA (1) MA26947A1 (enExample)
MX (1) MXPA03001311A (enExample)
MY (1) MY136065A (enExample)
NO (1) NO324941B1 (enExample)
NZ (1) NZ523990A (enExample)
PA (1) PA8525601A1 (enExample)
PE (1) PE20020291A1 (enExample)
PL (1) PL204215B1 (enExample)
PT (1) PT1313703E (enExample)
RS (1) RS51467B (enExample)
RU (1) RU2272027C2 (enExample)
SI (1) SI1313703T1 (enExample)
WO (1) WO2002016321A1 (enExample)
ZA (1) ZA200300894B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0300235A2 (hu) * 2000-03-21 2003-08-28 The Procter & Gamble Co. Heterociklikus oldalláncot tartalmazó, N-szubsztituált metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
US6713490B2 (en) 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
US8759400B2 (en) * 2005-12-19 2014-06-24 Methylgene Inc. Histone deacetylase inhibitors for enhancing activity of antifungal agents
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
JP2010513326A (ja) 2006-12-19 2010-04-30 メシルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害薬及びそのプロドラッグ
CN105683180B (zh) 2013-11-05 2020-01-21 阿斯利康(瑞典)有限公司 Nmda拮抗剂前药

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69420053T2 (de) * 1994-01-31 1999-11-25 Pfizer Inc., New York Neuroprotektive chroman verbindungen
DE4410822A1 (de) 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
TW498067B (en) 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
TWI254043B (en) 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor

Also Published As

Publication number Publication date
ZA200300894B (en) 2004-04-30
BR0113348A (pt) 2003-07-08
JP2004506715A (ja) 2004-03-04
ECSP034489A (es) 2003-03-31
EG24293A (en) 2009-01-08
RS51467B (sr) 2011-04-30
HRP20030125A2 (en) 2005-02-28
IL154254A0 (en) 2003-09-17
MY136065A (en) 2008-08-29
CZ2003492A3 (cs) 2004-01-14
EP1313703A1 (en) 2003-05-28
JP4162991B2 (ja) 2008-10-08
ES2299508T3 (es) 2008-06-01
CA2419279C (en) 2008-10-14
DK1313703T3 (da) 2008-05-19
DE60132782D1 (de) 2008-03-27
HUP0301548A2 (hu) 2003-08-28
AR030373A1 (es) 2003-08-20
DE60132782T2 (de) 2009-02-05
CN1227230C (zh) 2005-11-16
PT1313703E (pt) 2008-03-25
CZ303319B6 (cs) 2012-08-01
KR100589991B1 (ko) 2006-06-15
NZ523990A (en) 2004-09-24
KR20030022417A (ko) 2003-03-15
JO2289B1 (en) 2005-09-12
PA8525601A1 (es) 2002-04-25
AU2001285894B2 (en) 2006-06-15
PE20020291A1 (es) 2002-04-17
CN1447793A (zh) 2003-10-08
CA2419279A1 (en) 2002-02-28
US6407235B1 (en) 2002-06-18
RU2272027C2 (ru) 2006-03-20
EP1313703B1 (en) 2008-02-13
MA26947A1 (fr) 2004-12-20
NO20030781L (no) 2003-02-19
NO20030781D0 (no) 2003-02-19
CY1107937T1 (el) 2013-09-04
ATE386022T1 (de) 2008-03-15
US20020040037A1 (en) 2002-04-04
SI1313703T1 (sl) 2008-06-30
MXPA03001311A (es) 2003-06-30
AU8589401A (en) 2002-03-04
HRP20030125B1 (en) 2011-07-31
WO2002016321A1 (en) 2002-02-28
HUP0301548A3 (en) 2010-03-29
PL361387A1 (en) 2004-10-04
YU13003A (sh) 2006-05-25
HK1059083A1 (en) 2004-06-18
NO324941B1 (no) 2008-01-07
HU229802B1 (hu) 2014-07-28

Similar Documents

Publication Publication Date Title
EP0383579B1 (en) N-Phenyl-N-(4-piperidinyl)amides useful as analgesics
Feldman et al. Design, synthesis, and pharmacological evaluation of ultrashort-to long-acting opioid analgesics
DE60129210T2 (de) Zyklische amid-derivate
DE69518194T2 (de) Hydroxamsäure-Derivate mit drei Ringsubstituenten
BG107460A (bg) Производни на бензимидазола, тяхното получаване иприложението им в терапията
EP0319429A2 (en) 9-Acylamino-tetrahydroacridine derivatives and memory enhancing agent containing said derivative as active ingredient
JPH11509541A (ja) 新規なガランタミン誘導体、その製造方法、その医薬としての用途及びそれを含有する医薬組成物
PL204215B1 (pl) Pochodne fenylosulfonyloetylopiperydyny, środek leczniczy, sposób wytwarzania pochodnych fenylosulfonyloetylopiperydyny i ich zastosowanie
AU2001285894A1 (en) Prodrugs to NMDA receptor ligands
EP1097924A1 (en) 4-hydroxy-4-phenylpiperidine derivatives having -opioid agonist activity and pharmaceuticals containing the same
EP0389425B1 (de) Neue Benzothiopyranylamine
US5362736A (en) Isoquinoline derivatives
AU2014240139A1 (en) Muscarinic agonists
EP0663395A1 (de) 3-(Phenylalkylaminoalkyloxy)-5-phenylpyrazol-Derivate, Verfahren und Zwischenprodukte zu ihrer Herstellung und ihrer Verwendung als herzfrequenzsenkendes Mittel
WO1995025100A1 (fr) Utilisation d'esters de l'acide 4-amino-5-chloro-2-methoxybenzoique comme 5-ht4 agonistes
TWI306453B (en) Prodrugs to nmda receptor ligands, process for preparing the same and medicament comprising the same
EP0508004A1 (en) Phenylsulfonylalkanoic acid compounds
JPS6022711B2 (ja) トランス−デカハイドロキノリン誘導体，その製造法，及びそれを含む医薬

Legal Events

Date Code Title Description
RECP Rectifications of patent specification